Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT
Collinson F, Royle KL, Swain J, Ralph C, Maraveyas A, Eisen T, Nathan P, Jones R, Meads D, Wah TM, Martin A, Bestall J, Kelly-Morland C, Linsley C, Oughton J, Chan K, Theodoulou E, Arias-Pinilla G, Kwan A, Daverede L, Handforth C, Trainor S, Salawu A, McCabe C, Goh V, Buckley D, Hewison J, Gregory W, Selby P, Brown J, Brown J
Record ID 32011000720
English
Original Title:
A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)
Details
Project Status:
Completed
URL for project:
https://www.journalslibrary.nihr.ac.uk/programmes/hta/099121/#/
Year Published:
2024
URL for published report:
https://www.journalslibrary.nihr.ac.uk/hta/JWTR4127
Requestor:
NIHR Health Technology Assessment programme
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England, United Kingdom
MeSH Terms
- Withholding Treatment
- Kidney Neoplasms
- Sunitinib
- Carcinoma, Renal Cell
- Antineoplastic Agents
- Tyrosine Kinase Inhibitors
- Protein Kinase Inhibitors
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.